Medical Mythbusting Commentary for May 29, 2026

Source:
New weight loss procedure at Royal Alexandra Hospital being hailed a ‘game-changer’

Reference:
Endoscopic sleeve gastroplasty (ESG), GLP-1 receptor agonists, and bariatric surgery each offer distinct risk-benefit profiles, and the optimal choice depends on obesity class, patient preferences, comorbidities, and willingness to commit to long-term pharmacotherapy. Below is a comprehensive comparison.

—

Endoscopic Sleeve Gastroplasty: Outcomes

ESG achieves a mean total body weight loss (TBWL) of ~14–17% and excess weight loss (EWL) of ~49–53% at 12 months, with durable results showing ~15% TBWL maintained at 3–5 years.[1][2][3] The MERIT trial (the pivotal RCT) demonstrated 13.6% TBWL at 52 weeks vs. 0.8% in controls, with 77% of patients achieving ≥25% EWL; at 104 weeks, 68% maintained this threshold.[1] Comorbidity resolution is meaningful: diabetes remission ~55%, hypertension ~63%, and dyslipidemia ~56%.[3] The Obesity Society notes that 90% of patients maintain ≥5% TBWL and 61% maintain ≥10% TBWL at 5 years.[4]

The safety profile is favorable: serious adverse event rate is ~1–2%, with no mortality reported in the MERIT trial.[1][2] Mild events (nausea, vomiting, abdominal pain) are transient and resolve within days.[4] New-onset GERD is significantly lower than with laparoscopic sleeve gastrectomy (1.3% vs. 17.9%).[5] The procedure is reversible, though reversal is exceedingly rare (<0.01%).[4] Recovery is rapid (2–3 days vs. 2–6 weeks for surgical sleeve).[6]

—

Comparison: ESG vs. Laparoscopic Sleeve Gastrectomy (LSG)

LSG achieves greater weight loss (25–30% TBWL, 60–70% EWL) but carries higher procedural risk (5–10% adverse events), longer recovery, and significantly higher rates of new-onset GERD.[6][5] A large propensity-matched study of 3,018 pairs demonstrated that ESG was noninferior to LSG at the 10% TBWL margin, with similar comorbidity resolution for hypertension and dyslipidemia, though diabetes remission favored LSG (82% vs. 64%).[7] ESG is irreversible in terms of anatomy alteration with LSG, whereas ESG preserves native anatomy.[4][8]

—

Comparison: ESG vs. GLP-1 Receptor Agonists

Feature	ESG	GLP-1 RAs (semaglutide/tirzepatide)	References
TBWL at 12 months	~14–17%	~10–15% (semaglutide); up to ~21% (tirzepatide 15 mg)	[1], [2], [3]
Durability	Maintained at 3–5 years without ongoing treatment	Requires indefinite therapy; ~two-thirds of weight regained within 1 year of stopping	[1], [4], [5]
Procedure/treatment	One-time outpatient procedure (~60 min)	Weekly/daily injections indefinitely	[2], [6]
Serious adverse events	~1–2% (procedural)	Rare (10% SAEs); GI side effects in 47–84%	[1], [3]
Key risks	Procedural bleeding, perforation (rare); transient nausea/pain	GI symptoms (nausea, vomiting, diarrhea); gallbladder disease (RR 1.37); lean mass loss; rare pancreatitis	[6], [7], [8]
Cost (5-year)	One-time cost; more cost-effective over 5 years	Ongoing (~$12,000–16,000/year); $33,583 more than ESG over 5 years	[9]
Comorbidity improvement	Significant (diabetes, HTN, dyslipidemia)	Significant; additional CV benefit (SELECT trial)	[10], [11]
Reversibility	Reversible (preserves anatomy)	Fully reversible (stop medication)	[6]

A head-to-head RCT comparing ESG to liraglutide in class I–II obesity found that ESG produced faster weight loss in the first 6 months, but by 12 months the difference was no longer statistically significant, with liraglutide showing slower but more consistent weight loss.[17] Comorbidity resolution was similar between groups.[17]

A critical distinction is weight regain upon GLP-1 RA discontinuation: meta-analyses show patients regain approximately two-thirds of lost weight within one year of stopping semaglutide or tirzepatide.[11][12] ESG, by contrast, provides structural gastric restriction that maintains weight loss for years without ongoing treatment.[2][1]

The following figure from a JAMA Surgery study illustrates the weight loss trajectories of bariatric surgery vs. GLP-1 RAs over 24 months, demonstrating the substantially greater and more durable weight loss with surgical intervention:

Figure 2 Mean Weight Loss Outcomes at Baseline and During Follow-Up Period for Metabolic Bariatric Surgery (MBS) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) undefined

—

Combination Therapy: ESG + GLP-1 RAs

Emerging evidence supports combining ESG with GLP-1 RAs for enhanced outcomes. Addition of liraglutide 5 months after ESG resulted in superior TBWL (24.7% vs. 20.5%) and greater body fat reduction at 12 months compared to ESG alone.[19] This combination leverages complementary mechanisms — structural restriction from ESG plus central appetite suppression and hormonal modulation from GLP-1 RAs — and may represent the optimal strategy for patients seeking maximal weight loss without traditional surgery.[20][21]

—

Framework for Patient Counseling

The choice should be individualized based on several factors:

– Class I obesity (BMI 30–35): GLP-1 RAs (particularly tirzepatide) or ESG are both reasonable first-line options. Network meta-analyses suggest tirzepatide may be as effective as some surgical procedures in this BMI range. ESG is endorsed by IFSO for class I–II obesity.[22][2][23]

– Class II obesity (BMI 35–40): ESG, GLP-1 RAs, or bariatric surgery are all appropriate. ESG offers a middle ground — more effective than lifestyle alone, less invasive than surgery, and without the need for lifelong medication. A cost-effectiveness analysis found ESG dominant over semaglutide at 5 years, adding 0.06 QALYs while saving $33,583.[15]

– Class III obesity (BMI ≥40): Bariatric surgery (LSG or RYGB) remains the most effective intervention, achieving 25–30% TBWL with superior long-term metabolic outcomes. ESG may be considered for patients who refuse or do not qualify for surgery.[24][25][2]

– Patient preferences: For patients who prioritize avoiding procedures entirely, GLP-1 RAs are appropriate with the understanding that therapy is likely lifelong. For patients who want a durable, one-time intervention without the risks of traditional surgery, ESG is well-suited. For patients seeking maximum weight loss and metabolic improvement, bariatric surgery remains the benchmark.[26][27]

– Cardiovascular disease: GLP-1 RAs (semaglutide) have demonstrated cardiovascular benefit in the SELECT trial, which is a unique advantage not yet established for ESG.[16]

Obesity is a chronic, multifactorial disease, and the evidence increasingly supports a tiered, multimodal approach — lifestyle modification as the foundation, with pharmacotherapy, endoscopic procedures, and surgery deployed based on disease severity, patient goals, and response to prior interventions.[1][9][27]

—

Would you like to explore the specific protocols for combining ESG with GLP-1 receptor agonists, including optimal timing, dosing, and expected outcomes of combination therapy?

References

Contemporary Medical, Device, and Surgical Therapies for Obesity in Adults. Perdomo CM, Cohen RV, Sumithran P, Clément K, Frühbeck G. Lancet (London, England). 2023;401(10382):1116-1130. doi:10.1016/S0140-6736(22)02403-5.

Endoscopic Sleeve Gastroplasty for Treatment of Class 1 and 2 Obesity (MERIT): A Prospective, Multicentre, Randomised Trial. Abu Dayyeh BK, Bazerbachi F, Vargas EJ, et al. Lancet (London, England). 2022;400(10350):441-451. doi:10.1016/S0140-6736(22)01280-6.

IFSO Bariatric Endoscopy Committee Evidence-Based Review and Position Statement on Endoscopic Sleeve Gastroplasty for Obesity Management. Dayyeh BKA, Stier C, Alqahtani A, et al. Obesity Surgery. 2024;34(12):4318-4348. doi:10.1007/s11695-024-07510-z.

Medium-Term Weight Loss and Remission of Comorbidities Following Endoscopic Sleeve Gastroplasty: A Systematic Review and Meta-Analysis. Fehervari M, Fadel MG, Alghazawi LOK, et al. Obesity Surgery. 2023;33(11):3527-3538. doi:10.1007/s11695-023-06778-x.

Clinical Management of Obesity – Third Edition. Caroline M. Apovian MD, Louis Aronne MD, Sarah R. Barenbaum MD. The Obesity Society (2025).

Comparative Effectiveness and Safety Between Endoscopic Sleeve Gastroplasty and Laparoscopic Sleeve Gastrectomy: A Meta-Analysis of 6775 Individuals With Obesity. Beran A, Matar R, Jaruvongvanich V, et al. Obesity Surgery. 2022;32(11):3504-3512. doi:10.1007/s11695-022-06254-y.

Shaping the Future of Restrictive Bariatric Surgery: Clinical, Economic, and Long-Term Perspectives on Endoscopic and Laparoscopic Sleeve. Tripathi S, Ray AK, Sinha Y, Reid A, Noormohamed S. Obesity Surgery. 2025;:10.1007/s11695-025-08358-7. doi:10.1007/s11695-025-08358-7.

Endoscopic Gastroplasty Versus Laparoscopic Sleeve Gastrectomy: A Noninferiority Propensity Score-Matched Comparative Study. Alqahtani AR, Elahmedi M, Aldarwish A, Abdurabu HY, Alqahtani S. Gastrointestinal Endoscopy. 2022;96(1):44-50. doi:10.1016/j.gie.2022.02.050.

Endoscopic Sleeve Gastroplasty Versus Laparoscopic Sleeve Gastrectomy: Comparative Effectiveness, Safety, and Metabolic Outcomes: A Systematic Review and Evidence Synthesis. Alqahtani RS, Abdulrasoul MA, Khalil HH. Obesity Surgery. 2026;:10.1007/s11695-026-08667-5. doi:10.1007/s11695-026-08667-5.

Obesity Management in Adults: A Review. Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. JAMA. 2023;330(20):2000-2015. doi:10.1001/jama.2023.19897.

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Moiz A, Filion KB, Toutounchi H, et al. Annals of Internal Medicine. 2025;178(2):199-217. doi:10.7326/ANNALS-24-01590.

Discontinuing Glucagon-Like Peptide-1 Receptor Agonists and Body Habitus: A Systematic Review and Meta-Analysis. Berg S, Stickle H, Rose SJ, Nemec EC. Obesity Reviews : An Official Journal of the International Association for the Study of Obesity. 2025;26(8):e13929. doi:10.1111/obr.13929.

Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP‐1 Receptor Agonists. Shah E, AlShiab R, Abdo A, et al. Diabetes, Obesity & Metabolism. 2026;28(6):4546-4558. doi:10.1111/dom.70713.

Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. Mozaffarian D, Agarwal M, Aggarwal M, et al. The American Journal of Clinical Nutrition. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023.

Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. He L, Wang J, Ping F, et al. JAMA Internal Medicine. 2022;182(5):513-519. doi:10.1001/jamainternmed.2022.0338.

Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss. Haseeb M, Chhatwal J, Xiao J, Jirapinyo P, Thompson CC. JAMA Network Open. 2024;7(4):e246221. doi:10.1001/jamanetworkopen.2024.6221.

FDA Orange Book. FDA Orange Book.

Comparative Efficacy of Endoscopic Sleeve Gastroplasty (Esg) Versus Liraglutide in Weight Loss and Remission of Obesity-Related Comorbidities: Twelve Months Follow-Up Results. Nigro S, Vinciguerra F, Guccione F, et al. Obesity Surgery. 2025;:10.1007/s11695-025-08155-2. doi:10.1007/s11695-025-08155-2.

Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists. Barrett TS, Hafermann JO, Richards S, LeJeune K, Eid GM. JAMA Surgery. 2025;160(11):1232-1239. doi:10.1001/jamasurg.2025.3590.

Endoscopic Sleeve Gastroplasty Plus Liraglutide Versus Endoscopic Sleeve Gastroplasty Alone for Weight Loss. Badurdeen D, Hoff AC, Hedjoudje A, et al. Gastrointestinal Endoscopy. 2021;93(6):1316-1324.e1. doi:10.1016/j.gie.2020.10.016.

The Effect of Combining Surgical or Endoscopic Bariatric Interventions With Anti-Obesity Medication or Probiotics on Weight Loss: A Narrative Review. de Waal JR, Nieuwdorp M, Gerdes VEA. Frontiers in Endocrinology. 2026;17:1680182. doi:10.3389/fendo.2026.1680182.

Endobariatrics in the Era of Glucagon-Like Peptide-1 Receptor Agonists: Evolving Roles, Evidence, and Integration. Vahedi F, Yalamanchi M, Issa D. Current Opinion in Gastroenterology. 2025;41(6):380-388. doi:10.1097/MOG.0000000000001134.

Efficacy and Safety of European Medicines Agency (EMA)-approved Pharmacological, Endoscopic, and Surgical Treatments in Different Classes of Obesity: A Network Meta-Analysis of Randomised Controlled Trials for the Development of the SIO (Società Italiana Obesità) Italian Guidelines for the Diagnosis and Treatment of Overweight and Obesity. Barazzoni R, Monami M, Buscemi S, et al. Diabetes, Obesity & Metabolism. 2025;. doi:10.1111/dom.70204.

Current Recommendations for Procedure Selection in Class I and II Obesity Developed by an Expert Modified Delphi Consensus. Kermansaravi M, Chiappetta S, Parmar C, et al. Scientific Reports. 2024;14(1):3445. doi:10.1038/s41598-024-54141-6.

Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP-1 Receptor Agonists: A Network Meta-Analysis of Randomized Controlled Trials. Sabatella L, Ortega PM, Azcárate VV, et al. Obesity (Silver Spring, Md.). 2026;34(4):770-781. doi:10.1002/oby.70100.

Metabolic Bariatric Surgery Versus GLP-1 Receptor Agonists for Obesity Management: A Systematic Review and Meta-Analysis. Delgado LM, Barone G, Garcia G, et al. Obesity Surgery. 2026;36(4):1899-1908. doi:10.1007/s11695-026-08551-2.

Great Debates: Undergoing the Knife Versus Pill-Popping-the Comparative Efficacy and Cost-Effectiveness of Bariatric Surgery and GLP-1 Receptor Agonists in the Management of Obesity. Brosnihan P, Luce MS, Yetasook AK, et al. The American Surgeon. 2025;:31348251337145. doi:10.1177/00031348251337145.